Antimalarials in dermatology: Mechanism of action, Indications, and side effects;Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios

Actas Dermo-Sifiliograficas

Volumn 105, Issue 3, 2014, Pages 243-252

  Rodriguez Caruncho, C ^a   Bielsa Marsol, I ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antimalarials; Chloroquine; Hydroxychloroquine; Lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT;

ADVERSE DRUG REACTION; DERMATOLOGY; DRUG INDICATION; DRUG MECHANISM; HUMAN; OPHTHALMOLOGY; REVIEW; SCREENING; SKIN DISEASES;

ANTIMALARIALS; HUMANS; SKIN DISEASES;

EID: 84898749846     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2012.10.021     Document Type: Short Survey

References (141)

1. D.J. Wallace The history of antimalarials Lupus 5 1996 S2 S3
2. M.J. Van Beek, and W.W. Piette Antimalarials Dermatol Clin 19 2001 147 160
3. F. Page Treatment of lupus erythematosus with mepacrine Lancet 2 1951 755 758
4. J. Ducharme, and R. Farinotti Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements Clin Pharmacokinet 3 1996 257 274
5. S. Krishna, and N.J. White Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications Clin Pharmacokinet 30 1996 263 299
6. G. Sjölin-Forsberg, B. Berne, C. Blixt, M. Johansson, and B. Lindström Chloroquine phosphate: a long-term follow-up of drug concentrations in skin suction blister fluid and plasma Acta Derm Venereol 73 1993 426 429
7. N. Costedoat-Chalumeau, Z. Amoura, P. Duhaut, D.L. Huong, D. Sebbough, and B. Wechsler et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group Arthritis Rheum 48 2003 3207 3211
8. A.M. Kaufmann, and J.P. Krise Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications J Pharm Sci 96 2007 729 746
9. C. De Duve, T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. van Hoof Commentary. Lysosomotropic agents Biochem Pharmacol 23 1974 495 531
10. S. Kalia, and J.P. Dutz New concepts in antimalarial use and mode of action in dermatology Dermatol Ther 20 2007 160 174
11. A. Wozniacka, A. Carter, and D.P. McCauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus 11 2002 71 81
12. R.I. Fox Mechanism of action of hydroxychloroquine as an antirheumatic drug Semin Arthritis Rheum 23 1993 82 91
13. R. Fox Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development Lupus 5 1996 S4 S10
14. M. Jiménez Antipalúdicos: actualización de su uso en enfermedades reumáticas Reumatol Clin 2 2006 190 201
15. R.I. Rynes Antimalarial drugs in the treatment of rheumatological diseases Br J Rheumatol 36 1997 799 805
16. J. Bondeson, and R. Sundler Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis Gen Pharmacol 30 1998 357 366
17. I. Bielsa Uso de los antimaláricos en dermatología Piel 18 2003 515 518
18. R. Wolf, D. Wolf, and V. Ruocco Antimalarials: unapproved uses or indications Clin Dermatol 18 2000 17 35
19. T.Q. Nguyen, J.D. Capra, and R.D. Sontheimer 4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation Lupus 7 1998 148 153
20. B.P. Madow Use of antimalarial drugs as desludging agents in vascular disease processes J Am Med Assoc 172 1960 1630 1633
21. E. Bertrand, B. Cloitre, R. Ticolat, R.K. Bile, C. Gautier, and G.O. Abiyou et al. Antiaggregation action of chloroquine Med Trop (Mars) 50 1990 143 146
22. P.D. Winocour, R.L. Kinlough-Rathbone, and J.F. Mustard The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface Thromb Haemost 45 1981 257 262
23. E. Ernst, M. Rose, and R. Lee Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect Pharmatherapeutica 4 1984 48 52
24. R.G. Espinola, S.S. Pierangeli, A.E. Gharavi, and E.N. Harris Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies Thromb Haemost 87 2002 518 522
25. R. Nosál, V. Jancinová, and M. Petríková Chloroquine inhibits stimulated platelets at the arachidonic acid pathway Thromb Res 77 1995 531 542
26. G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron, and M.A. Khamashta Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review Ann Rheum Dis 69 2010 20 28
27. D.B. Pilcher Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients Am Surg 41 1975 761 766
28. J.R. Loudon Hydroxychloroquine and postoperative thromboembolism after total hip replacement Am J Med 85 1988 57 61
29. E. Johansson, K. Forsberg, and H. Johnsson Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement Haemostasis 10 1981 89 96
30. D.J. Wallace Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus Arthritis Rheum 30 1987 1435 1436
31. D. Erkan, Y. Yazici, M.G. Peterson, L. Sammaritano, and M.D. Lockshin A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome Rheumatology (Oxford) 41 2002 924 929
32. S.M. Toloza, A.G. Uribe, G. McGwin Jr., G.S. Alarcón, B.J. Fessler, and H.M. Bastian et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events Arthritis Rheum 50 2004 3947 3957
33. C.C. Mok, S.S. Tang, C.H. To, and M. Petri Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups Arthritis Rheum 52 2005 2774 2782
34. K.T. Ho, C.W. Ahn, G.S. Alarcón, B.A. Baethge, F.K. Tan, and J. Roseman et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events Rheumatology (Oxford) 44 2005 1303 1307
35. K. De Leeuw, B. Freire, A.J. Smit, H. Bootsma, C.G. Kallenberg, and M. Bijl Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus Lupus 15 2006 675 682
36. G. Ruiz-Irastorza, M.V. Egurbide, J.I. Pijoan, M. Garmendia, I. Villar, and A. Martinez-Berriotxoa et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus 15 2006 577 583
37. C.C. Mok, K.H. Tong, C.H. To, Y.P. Siu, L.Y. Ho, and T.C. Au Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study Medicine (Baltimore) 86 2007 203 209
38. H. Jung, R. Bobba, J. Su, Z. Shariati-Sarabi, D.D. Gladman, and M. Urowitz et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus Arthritis Rheum 62 2010 863 868
39. J. Sachet, E. Borba, E. Bonfa, C.G. Vinagre, V.M. Silva, and R.C. Maranhão Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients Lupus 16 2007 273 278
40. J. Muñoz-Valle, M. Vázquez-Del Mercado, S. Ruiz-Quezada, E. Oregón-Romero, R.E. Navarro-Hernández, and J. Ramírez- Barragán et al. Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine Rheumatol Int 23 2003 99 103
41. E. Borba, and E. Bonfá Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy J Rheumatol 28 2001 780 785
42. L. Tam, D. Gladman, D.C. Hallett, P. Rahman, and M.B. Urowitz Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus J Rheumatol 27 2000 2142 2145
43. L. Tam, E. Li, C.W. Lam, and B. Tomlinson Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease Lupus 9 2000 413 416
44. H. Hodis, F.J. Quismorio, E. Wickham, and D.H. Blankenhorn The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus J Rheumatol 20 1993 661 665
45. P. Rahman, D. Gladman, M.B. Urowitz, K. Yuen, D. Hallett, and I.N. Bruce The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs J Rheumatol 26 1999 325 330
46. M. Petri, C. Lakatta, L. Magder, and D. Goldman Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis Am J Med 96 1994 254 259
47. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533-40.
48. M. Petri Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis Lupus 5 1996 S16 S22
49. L.R. Rekedal, E. Massarotti, R. Garg, R. Bhatia, T. Gleeson, and B. Lu et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases Arthritis Rheum 62 2010 3569 3573
50. S.K. Penn, A.H. Kao, L.L. Schott, J.R. Elliott, F.G. Toledo, and L. Kuller et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus J Rheumatol 37 2010 1136 1142
51. C. Mok, A. Mak, and K. Ma Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus Lupus 14 2005 106 112
52. S. Lakshminarayanan, S. Walsh, and M. Mohanraj Factors associated with low bone mineral density in female patients with systemic lupus erythematosus J Rheumatol 28 2001 102 108
53. F.R. Ochsendorf Use of antimalarials in dermatology J Dtsch Dermatol Ges 8 2010 829 844
54. J.P. Callen Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients Arch Dermatol 118 1982 412 416
55. B.B. Furner Treatment of subacute cutaneous lupus erythematosus Int J Dermatol 29 1990 542 547
56. S. Wahie, A.K. Daly, H.J. Cordell, M.J. Goodfield, S.K. Jones, and C.R. Lovell et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study J Invest Dermatol 131 2011 1981 1986
57. A. Kreuter, R. Gaifullina, C. Tigges, J. Kirschke, P. Altmeyer, and T. Gambichler Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking Arch Dermatol 145 2009 244 248
58. The Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus N Engl J Med 324 1991 150 154
59. E. Tsakonas, L. Joseph, J.M. Esdaile, D. Choquette, J.L. Senécal, and A. Cividino et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group Lupus 7 1998 80 85
60. A.Y. Chang, E.W. Piette, K.P. Foering, T.R. Tenhave, J. Okawa, and V.P. Werth Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis Arch Dermatol 147 2011 1261 1267
61. P. Rahman, D.D. Gladman, and M.B. Urowitz Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus J Rheumatol 25 1998 1716 1719
62. M.L. Jewell, and D.P. McCauliffe Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment J Am Acad Dermatol 42 2000 983 987
63. E.W. Piette, K.P. Foering, A.Y. Chang, J. Okawa, T.R. Ten Have, and R. Feng et al. Impact of smoking in cutaneous lupus erythematosus Arch Dermatol 148 2012 317 322
64. F.D. Malkinson, and L. Levitt Hydroxychloroquine treatment of porphyria cutanea tarda Arch Dermatol 116 1980 1147 1150
65. R.E. Ashton, J.L. Hawk, and I.A. Magnus Low-dose oral chloroquine in the treatment of porphyria cutanea tarda Br J Dermatol 111 1984 609 613
66. C.S. Petersen, and K. Thomsen High-dose hydroxychloroquine treatment of porphyria cutanea tarda J Am Acad Dermatol 26 1992 614 619
67. V. Valls, J. Ena, and R. Enríquez-de-Salamanca Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload J Dermatol Sci 7 1994 169 175
68. G. Swanbeck, and G. Wennersten Treatment of porphyria cutanea tarda with chloroquine and phlebotomy Br J Dermatol 97 1977 77 81
69. G. Wennersten, and A.M. Ros Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy Acta Derm Venereol Suppl (Stockh) 100 1982 119 123
70. W.M. Jaremko, E.H. Beutner, V. Kumar, H. Kipping, P. Condry, and M.Y. Zeid et al. Chronic ulcerative stomatitis associated with a specific immunologic marker J Am Acad Dermatol 22 1990 215 220
71. A. Parodi, and P.P. Cardo Patients with erosive lichen planus may have antibodies directed to a nuclear antigen of epithelial cells: a study on the antigen nature J Invest Dermatol 94 1990 689 693
72. J.E. Lewis, E.H. Beutner, R. Rostami, and T.P. Chorzelski Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies Int J Dermatol 35 1996 272 275
73. M.W. Carlson, J.A. Garlick, and L.W. Solomon Chronic ulcerative stomatitis: evidence of autoimmune pathogenesis Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111 2011 742 748
74. L.W. Solomon, M.E. Neiders, M.G. Zwick, K.L. Kirkwood, and V. Kumar Autoimmunity to deltaNp63alpha in chronic ulcerative stomatitis J Dent Res 86 2007 826 831
75. L.A. Lee, P. Walsh, C.A. Prater, L.J. Su, A. Marchbank, and T.B. Egbert et al. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family J Invest Dermatol 113 1999 146 151
76. T.Y. Woo, J.P. Callen, J.J. Voorhees, D.R. Bickers, R. Hanno, and C. Hawkins Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine J Am Acad Dermatol 10 1984 592 600
77. R.D. Quain, and V.P. Werth Management of cutaneous dermatomyositis: current therapeutic options Am J Clin Dermatol 7 2006 341 351
78. A. Cosnes, F. Amaudric, R. Gherardi, J. Verroust, J. Wechsler, and J. Revuz et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids Arch Dermatol 131 1995 1381 1385
79. G.C. Ang, and V.P. Werth Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study Arch Dermatol 141 2005 855 859
80. N.H. Cox Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine Br J Dermatol 132 1995 1016 1017
81. N.Y. Olson, and C.B. Lindsley Adjunctive use of hydroxychloroquine in childhood dermatomyositis J Rheumatol 16 1989 1545 1547
82. M.T. Pelle, and J.P. Callen Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus Arch Dermatol 138 2002 1231 1233
83. B. Shaffer, M. Cahn, and E. Levy Sarcoidosis apparently cured by quinacrine (Atabrine) hydrochloride Arch Dermatol 67 1953 640 641
84. S. Modi, and T. Rosen Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate Cutis 81 2008 351 354
85. E. Jones, and J.P. Callen Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas J Am Acad Dermatol 23 1990 487 489
86. D. Meyersburg, M.P. Schön, H.P. Bertsch, and C.S. Seitz Uncommon cutaneous ulcerative and systemic sarcoidosis. Successful treatment with hydroxychloroquine and compression therapy Hautarzt 62 2011 691 695
87. H. Brodthagen Chloroquine in pulmonary sarcoidosis Lancet 1 1968 1157
88. D. Davies Sarcoidosis treated with chloroquine Br J Dis Chest 57 1963 30 36
89. British Tuberculosis Association Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association Tubercle 48 1967 257 272
90. O.P. Sharma Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement Arch Neurol 55 1998 1248 1254
91. M.P. Rabinowitz, and A.P. Murchison Orbital sarcoidosis treated with hydroxychloroquine Orbit 30 2011 13 15
92. P.E. Barré, M. Gascon-Barré, J.L. Meakins, and D. Goltzman Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis Am J Med 82 1987 1259 1262
93. S. Hassid, G. Choufani, S. Saussez, M. Dubois, I. Salmon, and A. Soupart Sarcoidosis of the paranasal sinuses treated with hydroxychloroquine Postgrad Med J 74 1998 172 174
94. N. Joundy, S. Carpentier, C. Leclech, C. Aubé, M.C. Rousselet, and P. Barré et al. Favourable course of a pseudotumoral form of hepatic and splenic sarcoidosis under treatment with hydroxychloroquine and colchicine Gastroenterol Clin Biol 19 1995 1066 1068
95. M. Cahn, E. Levy, and B. Shaffer Polymorphous light eruption; the effect of chloroquine phosphate in modifying reactions to ultra-violet light J Invest Dermatol 26 1956 201 207
96. R.S. Lester, T.K. Burnham, G. Fine, and K. Murray Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine Arch Dermatol 96 1967 1 10
97. J.V. Christiansen, and H. Brodthagen The treatment of polymorphic light eruptions with chloroquine Br J Dermatol 68 1956 204 208
98. M.F. Corbett, J.L. Hawk, A. Herxheimer, and I.A. Magnus Controlled therapeutic trials in polymorphic light eruption Br J Dermatol 107 1982 571 581
99. G.M. Murphy, J.L. Hawk, and I.A. Magnus Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring Br J Dermatol 116 1987 379 386
100. M. Simon Jr., and P. von den Driesch Antimalarials for control of disseminated granuloma annulare in children J Am Acad Dermatol 31 1994 1064 1065
101. C. Cannistraci, I. Lesnoni La Parola, M. Falchi, and M. Picardo Treatment of generalized granuloma annulare with hydroxychloroquine Dermatology 211 2005 167 168
102. A. Masmoudi, W. Abdelmaksoud, H. Turki, M. Hachicha, S. Marrekchi, and M. Mseddi et al. Beneficial effects of antimalarials in the treatment of generalized granuloma annular in children Tunis Med 84 2006 125 127
103. D. Eisen Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial J Am Acad Dermatol 28 1993 609 612
104. S.E. Albers, L.F. Glass, and N.A. Fenske Lichen planus subtropicus: direct immunofluorescence findings and therapeutic response to hydroxychloroquine Int J Dermatol 33 1994 645 647
105. C. Chiang, D. Sah, B.K. Cho, B.E. Ochoa, and V.H. Price Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system J Am Acad Dermatol 62 2010 387 392
106. A. Samrao, A.L. Chew, and V. Price Frontal fibrosing alopecia: a clinical review of 36 patients Br J Dermatol 163 2010 1296 1300
107. K. Nguyen, K. Washenik, and J. Shupack Necrobiosis lipoidica diabeticorum treated with chloroquine J Am Acad Dermatol 46 2002 S34 S36
108. B.J. Kelly, M.E. Mrstik, F.A. Ramos-Caro, and K.A. Iczkowski Papular elastolytic giant cell granuloma responding to hydroxychloroquine and quinacrine Int J Dermatol 43 2004 964 966
109. H.W. Lim, W.L. Morison, R. Kamide, M.R. Buchness, R. Harris, and N.A. Soter Chronic actinic dermatitis. An analysis of 51 patients evaluated in the United States and Japan Arch Dermatol 130 1994 1284 1289
110. H.A. Haynes, J.D. Bernhard, and R.W. Gange Actinic reticuloid. Response to combination treatment with azathioprine, hydroxychloroquine, and prednisone J Am Acad Dermatol 10 1984 947 952
111. M. Magaña-García Antimalarials for children J Am Acad Dermatol 30 1994 510
112. J.H. Epstein, J.J. Vandenberg, and W.L. Wright Solar urticaria Arch Dermatol 88 1963 135 141
113. S.H. Wakelin, and M.P. James Extensive lichen sclerosus et atrophicus with bullae and ulceration - improvement with hydroxychloroquine Clin Exp Dermatol 19 1994 332 334
114. S. Lakhanpal, W.W. Ginsburg, C.J. Michet, J.A. Doyle, and S.B. Moore Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases Semin Arthritis Rheum 17 1988 221 231
115. T.W. Baer Epidermolysis bullosa hereditaria treated with antimalarials Arch Dermatol 84 1961 503 504
116. C. Dorsey Dystrophic epydermolysis bullosa treated with chloroquine Arch Dermatol 79 1959 122 123
117. K.R. Schultz, S. Bader, J. Paquet, and W. Li Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease Blood 86 1995 4344 4352
118. J.A. Alloway, and L.K. Franks Hydroxychloroquine in the treatment of chronic erythema nodosum Br J Dermatol 132 1995 661 662
119. R.U. Sorensen, C. Abramowsky, and R.C. Stern Corticosteroid-sparing effect of hydroxychloroquine in a patient with early-onset Weber-Christian syndrome J Am Acad Dermatol 23 1990 1172 1174
120. M. Easterbrook An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine J Rheumatol 26 1999 1866 1868
121. M.F. Marmor, U. Kellner, T.Y. Lai, J.S. Lyons, and W.F. Mieler Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Ophthalmology 118 2011 415 422
122. F. Wolfe, and M.F. Marmor Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus Arthritis Care Res (Hoboken) 62 2010 775 784
123. M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, W.F. Mieler American Academy of Ophthalmology Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology Ophthalmology 109 2002 1377 1382
124. J.A. Jover, L. Leon, E. Pato, E. Loza, Z. Rosales, and M.A. Matias et al. Long-term use of antimalarial drugs in rheumatic diseases Clin Exp Rheumatol 30 2012 380 387
125. P.H. Asch, P. Caussade, C. Marquart-Elbaz, N. Boehm, and E. Grosshans Chloroquine-induced achromotrichia. An ultrastructural study Ann Dermatol Venereol 124 1997 552 556
126. W.Q. Ward, W.G. Walter-Ryan, and G.M. Shehi Toxic psychosis: a complication of antimalarial therapy J Am Acad Dermatol 12 1985 863 865
127. R.L. Evans, S. Khalid, and J.L. Kinney Antimalarial psychosis revisited Arch Dermatol 120 1984 765 767
128. A.G. Tristano, L. Falcón, M. Willson, and I.M. de Oca Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus Rheumatol Int 24 2004 315 316
129. C. Wang, P.R. Fortin, Y. Li, T. Panaritis, M. Gans, and J.M. Esdaile Discontinuation of antimalarial drugs in systemic lupus erythematosus J Rheumatol 26 1999 808 815
130. J.P. Baguet, F. Tremel, and M. Fabre Chloroquine cardiomyopathy with conduction disorders Heart 81 1999 221 223
131. N. Costedoat-Chalumeau, J.S. Hulot, Z. Amoura, G. Leroux, P. Lechat, and C. Funck-Brentano et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases Rheumatology 46 2007 808 810
132. A. Wozniacka, I. Cygankiewicz, M. Chudzik, A. Sysa-Jedrzejowska, and J.K. Wranicz The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters Lupus 15 2006 521 525
133. A. Wozniacka, and D.P. McCauliffe Optimal use of antimalarials in treating cutaneous lupus erythematosus Am J Clin Dermatol 6 2005 1 11
134. N. Costedoat-Chalumeau, Z. Amoura, G. Aymard, T.H. Le, B. Wechsler, and D. Vauthier et al. Evidence of transplacental passage of hydroxychloroquine in humans Arthritis Rheum 46 2002 1123 1124
135. M. Levy, D. Buskila, and D. Gladman et al. Pregnancy outcome following first trimester exposure to chloroquine Am J Perinatol 8 1991 174 178
136. A. Parke, and B. West Hydroxychloroquine in pregnant patients with systemic lupus erythematosus J Rheumatol 23 1996 1715 1718
137. N. Buchanan, E. Toubi, and M. Khamashta et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases Ann Rheum Dis 55 1996 486 488
138. G. Klinger, Y. Morad, and C. Westall et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases Lancet 358 2001 813 814
139. N. Costedoat-Chalumeau, Z. Amoura, and P. Duhaut et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group Arthritis Rheum 48 2003 3207 3211
140. E. Borba, J. Turrini-Filho, and K. Kuruma et al. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry Lupus 13 2004 223 227
141. M. Motta, A. Tincani, and D. Faden et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation J Perinatol 25 2005 86 89